Glu - 4
Art:
714177-00N
Rev. Date: 03-Aug-12
β–Hydroxybutyrate
6.0
14
Lactate
6.6
Maltose
13.3
Pyruvate
0.31
Salicylate
4.34
Uric Acid
1.4
Notes:
1) Acetaminophen has been shown to interfere with glucose results in the i-STAT 6+, EC8+, EC4+ and
G products, at a concentration prescribed by the CLSI guideline, 1.32 mmol/L, which represents a toxic
concentration of acetaminophen. Acetaminophen at 0.132 mmol/L, which represents the upper end of the
therapeutic concentration, has been shown not to significantly interfere with i-STAT glucose results for all
i-STAT cartridges. Acetaminophen at a test level of 1.32 mmol/L (toxic concentration) has been shown
not to significantly interfere with glucose results in the i-STAT CHEM8+ and CG8+ products.
2) Acetylcysteine has been tested at two levels; the CLSI recommended level and a concentration of
0.30 mmol/L. The latter is 3 times the peak plasma therapeutic concentration associated with treatment
to reverse acetaminophen poisoning. APOC has not identified a therapeutic condition that would lead
to levels consistent with the CLSI recommended level. Acetylcysteine at a concentration of 10.2 mmol/L
decreased i-STAT glucose results, while acetylcysteine at a concentration of 0.3 mmol/L did not signifi-
cantly interfere with i-STAT glucose results.
3) Bromide has been tested at two levels; the CLSI recommended level and a therapeutic plasma con-
centration level of 2.5 mmol/L. The latter is the peak plasma concentration associated with halothane
anesthesia, in which bromide is released. APOC has not identified a therapeutic condition that would lead
to levels consistent with the CLSI recommended level. Bromide at a concentration of 37.5 mmol/L sig-
nificantly decreased i-STAT glucose results. Bromide at a concentration of 2.5 mmol/L decreased i-STAT
glucose results by approximately 5 mg/dL on cartridges heated to 37°C (CG8+, CHEM8+) and at higher
levels on cartridges not heated to 37°C (EC8+, 6+, EC4+). Consider using the CG8+ or CHEM8+ car-
tridge when testing blood from patients undergoing halothane anesthesia.
4) Hydroxyurea is a DNA synthesis inhibitor used in the treatment of various forms of cancer, sickle cell
anemia, and HIV infection. This drug is used to treat malignancies including melanoma, metastatic ovar-
ian cancer, and chronic myelogenous leukemia. It is also used in the treatment of polycythemia vera,
thrombocythemia, and psoriasis. At typical doses ranging from 500 mg to 2 g/day, concentrations of
hydroxyurea in patients’ blood may be sustained at approximately 100 to 500 µmol/L. Higher concentra-
tions may be observed soon after dosing or at higher therapeutic doses.
5) The dependence of the i-STAT glucose with respect to pH is as follows: Values below 7.4 at 37°C
decrease results by approximately 0.9 mg/dL (0.05 mmol/L) per 0.1 pH units. Values above 7.4 at 37°C
increase results by approximately 0.8 mg/dL (0.04 mmol/L) per 0.1 pH units.
6) The dependence of the i-STAT glucose with respect to pO
2
is as follows: Oxygen levels of less than 20
mmHg (2.66 kPa) at 37°C may decrease results.
* It is possible that other interfering substance may be encountered. The degree of interference at concentrations other than those listed might not be
predictable.
Summary of Contents for i-STAT 1
Page 1: ...i STAT 1 System Manual Rev Date 20 Jan 12 Art 714336 00L ...
Page 18: ...1 8 Art 714363 00U Rev Date 02 Aug 12 ...
Page 44: ......
Page 90: ......
Page 106: ...9 12 Art 714371 00E Rev Date 06 Aug 12 ...
Page 162: ......
Page 166: ...Art 730292 00A Rev Date 20 Feb 12 4 ...
Page 176: ...10 10 Art 714372 00L Rev Date 30 Jul 12 ...
Page 182: ...11 6 Art 714373 00F Rev Date 17 Jan 11 ...
Page 184: ...12 2 Art 714374 00J Rev Date 25 Aug 11 ...
Page 185: ...Art 714374 00J Rev Date 25 Aug 11 12 3 ...
Page 186: ...12 4 Art 714374 00J Rev Date 25 Aug 11 ...
Page 187: ...Art 714374 00J Rev Date 25 Aug 11 12 5 ...
Page 192: ......
Page 194: ......
Page 214: ...14 20 Art 714376 00M Rev Date 31 Jan 12 ...
Page 216: ...14 22 Art 714376 00M Rev Date 31 Jan 12 ...
Page 218: ...14 24 Art 714376 00M Rev Date 31 Jan 12 ...
Page 220: ...14 26 Art 714376 00M Rev Date 31 Jan 12 ...
Page 222: ...14 28 Art 714376 00M Rev Date 31 Jan 12 ...
Page 224: ...14 30 Art 714376 00M Rev Date 31 Jan 12 ...
Page 226: ......
Page 236: ......
Page 252: ...17 4 Art 714379 00F Rev Date 18 Jul 12 ...
Page 254: ......
Page 294: ...Art 725768 00E Rev Date 04 Jan 12 20 ...
Page 336: ...22 2 Art 714384 00D Rev Date 07 18 06 ...
Page 342: ...22 8 Art 714384 00D Rev Date 07 18 06 ...
Page 348: ...22 14 Art 714384 00D Rev Date 07 18 06 ...
Page 352: ...22 18 Art 714384 00D Rev Date 07 18 06 ...
Page 364: ...22 30 Art 714384 00D Rev Date 07 18 06 ...
Page 384: ...22 50 Art 714384 00D Rev Date 07 18 06 ...
Page 404: ...22 70 Art 714384 00D Rev Date 07 18 06 ...
Page 488: ...Kaolin ACT 4 Art 715878 00M Rev Date 31 Jan 12 ...
Page 536: ......
Page 556: ...Art 714261 00E Rev Date 10 Jan 11 8 ...
Page 560: ...Art 716240 00D Rev Date 03 Mar 10 4 ...
Page 572: ...Art 715617 00D Rev Date 06 11 08 ...
Page 578: ...Art 714547 00F Rev Date 06 11 08 ...
Page 590: ...Art 720735 00B Rev Date 06 11 08 ...
Page 592: ...Art 721106 00B Rev Date 06 11 08 ...
Page 598: ...Art 722831 00A Rev Date 19 Feb 09 ...
Page 610: ...Art 720654 00B Rev Date 06 11 08 ...
Page 614: ...Art 721317 00D Rev Date 13 Aug 12 4 ...
Page 616: ...Art 725703 00A Rev Date 08 Mar 10 2 ...
Page 618: ...Art 721296 00A Rev Date 07 16 08 ...
Page 620: ...REV DATE 16 Oct 12 ART 714446 00L ...
Page 627: ...PROCEDURE MANUAL FOR THE i STAT SYSTEM 6 REV DATE 16 Oct 12 ART 714446 00L ...
Page 628: ...PROCEDURE MANUAL FOR THE i STAT SYSTEM 7 REV DATE 16 Oct 12 ART 714446 00L ...
Page 629: ...PROCEDURE MANUAL FOR THE i STAT SYSTEM 8 REV DATE 16 Oct 12 ART 714446 00L ...
Page 630: ...PROCEDURE MANUAL FOR THE i STAT SYSTEM 9 REV DATE 16 Oct 12 ART 714446 00L ...
Page 658: ......